Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis

Clinical Rheumatology

Volumn 32, Issue 10, 2013, Pages 1467-1474

  Hudson, Marie ^a,b,c   Assayag, Deborah ^c   Caron, Melissa ^b   Fox, Benjamin D ^c,d   Hirsch, Andrew ^a,c   Steele, Russell ^b,e   Gaudreau Taillefer, Rebecca ^b   Tatibouet, Solène ^b   Rudski, Lawrence ^a,c   Baron, Murray ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d TEL AVIV UNIVERSITY   (Israel)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Diffusion capacity of the lung for carbon monoxide; DLCO; Forced vital capacity; FVC; Interstitial lung disease; Lung function; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; CENTROMERE ANTIBODY; HEMOGLOBIN; HEMOGLOBIN VARIANT;

ADULT; ANEMIA; ARTICLE; DISEASE DURATION; DYSPNEA; FEMALE; FORCED VITAL CAPACITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEART CATHETERIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG DIFFUSION CAPACITY FOR CARBON MONOXIDE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; SHORT FORM 36; SMOKING; SOCIAL INTERACTION; SYSTEMIC SCLEROSIS; TERTIARY HEALTH CARE; VISUAL ANALOG SCALE;

AGED; CARBON MONOXIDE; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TIME FACTORS; VITAL CAPACITY;

EID: 84885308187     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2301-8     Document Type: Article

References (38)

1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66(7):940-4
2. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29(2):371-90
3. Steele R, Hudson M, Lo E, Baron M (2011) A clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 64(4):519-24
4. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088-93
5. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, et al. (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39(10):682-91
6. Horstman M, Mertens F, Stam H (2005) Transfer factor for carbon monoxide. In: Gosselink R, Stam H (eds) Lung function testing, vol 10, European Respiratory Society monograph., pp 127-147
7. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962-70
8. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248-54
9. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 66(6):754-63
10. Quadrelli SA, Molinari L, Ciallella LM, Bosio M, Salvado A (2009) Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis. Rheumatol Int 29(9):995-9
11. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F (1984) Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 63(4):221-31
12. Broholm B, Ullman S, Halberg P, Jacobsen S (2008) Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis. Clin Rheumatol 27(8):1053-6
13. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57(2):318-26
14. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE (2006) Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 55(4):598-602
15. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YMRM, Draeger HT, et al. (2010) Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 12(5):R166
16. Jacobsen S, Halberg P, Ullman S, Hoier-Madsen M, Petersen J, Mortensen J, et al. (1997) A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 16(4):384-90
17. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med 354(25):2655-66
18. Meune C, Avouac J, Airo P, Beretta L, Dieude P, Wahbi K, et al. (2011) Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 63(9):2790-6
19. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36(2):239-43
20. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. (2007) Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56(6):2005-12
21. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720-35
22. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281-5
23. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202-5
24. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35(3):458-65
25. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137-45
26. Steen VD, Medsger TA Jr (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40(11):1984-91
27. Ware JE Jr, Sherbourne CD (1992) The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483
28. Hewlett S, Hehir M, Kirwan JR (2007) Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 57(3):429-39
29. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ (2007) Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 34(7):1528-34
30. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35(7):765-70
31. Hinchcliff M, Fischer A, Schiopu E, Steen VD (2011) Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 38(10):2172-9
32. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35-42
33. Fischer A, Bull TM, Steen VD (2012) Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 64(3):303-10
34. Steen VD (2005) The lung in systemic sclerosis. J Clin Rheumatol 11(1):40-6
35. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, le Boutin TH, et al. (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54(1):184-91
36. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC (1993) Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 16:41-52
37. Hughes JM, Pride NB (2001) In defence of the carbon monoxide transfer coefficient Kco (TL/VA). Eur Respir J 17(2):168-74
38. Cotes JE (2001) Carbon monoxide transfer coefficient KCO (TL/VA): a flawed index. Eur Respir J 18(5):893-4